Published in J Biol Chem on November 27, 2012
Chromatinized protein kinase C-θ directly regulates inducible genes in epithelial to mesenchymal transition and breast cancer stem cells. Mol Cell Biol (2014) 0.95
Mechanotransduction at the basis of endothelial barrier function. Tissue Barriers (2013) 0.93
Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study. PLoS One (2013) 0.91
Triclosan potentiates epithelial-to-mesenchymal transition in anoikis-resistant human lung cancer cells. PLoS One (2014) 0.87
Role of epithelial mesenchymal transition in prostate tumorigenesis. Curr Pharm Des (2015) 0.83
LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a. Mol Cancer Res (2015) 0.82
MRC-5 fibroblast-conditioned medium influences multiple pathways regulating invasion, migration, proliferation, and apoptosis in hepatocellular carcinoma. J Transl Med (2015) 0.80
EPLIN: a fundamental actin regulator in cancer metastasis? Cancer Metastasis Rev (2015) 0.75
Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science (1986) 15.84
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol (2001) 5.82
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell (2005) 4.48
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell (2003) 3.87
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Identification of substrate recognition determinants for human ERK1 and ERK2 protein kinases. J Biol Chem (1991) 3.37
EPLIN mediates linkage of the cadherin catenin complex to F-actin and stabilizes the circumferential actin belt. Proc Natl Acad Sci U S A (2007) 2.82
Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res (2003) 2.47
Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res (2009) 2.34
Mechanisms of bone metastasis. Cancer (1997) 2.29
Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol (2001) 2.24
Targeting proteins for degradation. Nat Chem Biol (2009) 2.22
Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer (2006) 2.04
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res (2002) 2.01
Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene (2010) 1.91
Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res (1991) 1.87
Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem (2007) 1.87
Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate (2006) 1.80
Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis (2008) 1.64
cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene (2007) 1.58
Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis (2005) 1.55
EPLIN regulates actin dynamics by cross-linking and stabilizing filaments. J Cell Biol (2003) 1.48
Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci U S A (1996) 1.44
EPLIN, epithelial protein lost in neoplasm. Oncogene (1999) 1.38
ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia (2010) 1.36
β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res (2011) 1.33
Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol (2007) 1.31
Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer (2005) 1.20
Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis. Clin Exp Metastasis (2006) 1.19
Extracellular signal-regulated kinase/mitogen-activated protein kinase regulates actin organization and cell motility by phosphorylating the actin cross-linking protein EPLIN. Mol Cell Biol (2007) 1.17
Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. Prostate (2006) 1.14
Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer (2011) 1.08
Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer (2004) 1.08
Inhibition of anchorage-independent growth of transformed NIH3T3 cells by epithelial protein lost in neoplasm (EPLIN) requires localization of EPLIN to actin cytoskeleton. Mol Biol Cell (2002) 1.07
Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol Cancer (2008) 1.07
A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int (2007) 1.01
EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis. Oncogene (2011) 1.00
Characterization of the human EPLIN (Epithelial Protein Lost in Neoplasm) gene reveals distinct promoters for the two EPLIN isoforms. Gene (2000) 0.99
Epithelial protein lost in neoplasm (EPLIN) interacts with α-catenin and actin filaments in endothelial cells and stabilizes vascular capillary network in vitro. J Biol Chem (2011) 0.94
Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol (2008) 0.92
Fibroblasts are critical determinants in prostatic cancer growth and dissemination. Cancer Metastasis Rev (1991) 0.90
TGFβ and EGF synergistically induce a more invasive phenotype of epithelial ovarian cancer cells. Biochem Biophys Res Commun (2010) 0.87
EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. Prostate (2009) 0.86
New advances on prostate carcinogenesis and therapies: involvement of EGF-EGFR transduction system. Growth Factors (2003) 0.86
Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res (2008) 0.86
The impact of EPLINα (Epithelial protein lost in neoplasm) on endothelial cells, angiogenesis and tumorigenesis. Angiogenesis (2010) 0.81
Epithelial Protein Lost in Neoplasm alpha (Eplin-alpha) is transcriptionally regulated by G-actin and MAL/MRTF coactivators. Mol Cancer (2010) 0.79
EPLIN is a negative regulator of prostate cancer growth and invasion. J Urol (2011) 0.78
EPLIN-α expression in human oesophageal cancer and its impact on cellular aggressiveness and clinical outcome. Anticancer Res (2012) 0.77
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol (2004) 17.47
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol (2007) 7.33
Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res (2008) 5.67
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
Recent advances in head and neck cancer. N Engl J Med (2008) 5.05
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet (2006) 4.22
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet (2002) 4.03
Two Dobzhansky-Muller genes interact to cause hybrid lethality in Drosophila. Science (2006) 3.77
NMR structure determination for larger proteins using backbone-only data. Science (2010) 3.00
A route to brightly fluorescent carbon nanotubes for near-infrared imaging in mice. Nat Nanotechnol (2009) 2.85
Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew Chem Int Ed Engl (2011) 2.79
Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res (2008) 2.67
Synthesis, structure, and bioactivity of N'-substituted benzylidene-3,4,5-trimethoxybenzohydrazide and 3-acetyl-2-substituted phenyl-5-(3,4,5-trimethoxyphenyl)-2,3-dihydro-1,3,4-oxadiazole derivatives. Bioorg Med Chem Lett (2006) 2.62
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell (2011) 2.61
The incidence and risk factors for developing dry eye after myopic LASIK. Am J Ophthalmol (2006) 2.58
XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology (2010) 2.55
Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc (2007) 2.45
Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol (2005) 2.43
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res (2005) 2.43
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell (2012) 2.39
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther (2006) 2.38
A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano (2010) 2.27
Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer (2009) 2.26
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res (2005) 2.21
Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine (2008) 2.20
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol (2005) 2.18
Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin (2008) 2.15
Meta-analysis added power to identify variants in FTO associated with type 2 diabetes and obesity in the Asian population. Obesity (Silver Spring) (2010) 2.15
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell (2013) 2.11
Head and neck cancer chemoprevention gets a shot in the arm. J Clin Oncol (2008) 2.09
FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res (2006) 2.03
Phenotypic characterization of human corneal epithelial cells expanded ex vivo from limbal explant and single cell cultures. Exp Eye Res (2004) 2.02
Perspectives for cancer prevention with natural compounds. J Clin Oncol (2009) 1.99
MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol (2010) 1.98
Cancer prevention with natural compounds. Semin Oncol (2010) 1.98
Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer (2002) 1.97
Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci (2004) 1.95
ABCG2 transporter identifies a population of clonogenic human limbal epithelial cells. Stem Cells (2005) 1.95
The influence of cardiopulmonary bypass priming without FFP on postoperative coagulation and recovery in pediatric patients with cyanotic congenital heart disease. Eur J Pediatr (2014) 1.95
Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol (2007) 1.81
Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes (2014) 1.81
Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. J Urol (2007) 1.81
Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate (2006) 1.80
MR imaging of pulmonary embolism: diagnostic accuracy of contrast-enhanced 3D MR pulmonary angiography, contrast-enhanced low-flip angle 3D GRE, and nonenhanced free-induction FISP sequences. Radiology (2012) 1.79
Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. Invest Ophthalmol Vis Sci (2007) 1.78
Lymphoid neoplasms of the urinary tract and male genital organs: a clinicopathological study of 40 cases. Mod Pathol (2009) 1.76
JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res (2005) 1.76
Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol (2009) 1.74
Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circ Res (2010) 1.74
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans. Vaccine (2010) 1.65
Oxygen isotopes of East Asian dinosaurs reveal exceptionally cold Early Cretaceous climates. Proc Natl Acad Sci U S A (2011) 1.65
Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res (2008) 1.64
Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis (2008) 1.64
Prognostic accuracy of computed tomography findings for patients with laryngeal cancer undergoing laryngectomy. J Clin Oncol (2010) 1.64
Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol (2008) 1.63
Novel CACNA1S mutation causes autosomal dominant hypokalemic periodic paralysis in a Chinese family. J Mol Med (Berl) (2005) 1.63
Lipid interaction converts prion protein to a PrPSc-like proteinase K-resistant conformation under physiological conditions. Biochemistry (2007) 1.62
Rationale for regular reporting on health disparities and inequalities - United States. MMWR Surveill Summ (2011) 1.61
Preparation of carbon nanotube bioconjugates for biomedical applications. Nat Protoc (2009) 1.61
Methamphetamine enhances HIV infection of macrophages. Am J Pathol (2008) 1.60
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol (2011) 1.59
Radiation modulation of microRNA in prostate cancer cell lines. Prostate (2008) 1.58
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) (2013) 1.56
Antioxidant effect of zinc in humans. Free Radic Biol Med (2004) 1.56
A genome-wide approach to identifying novel-imprinted genes. Hum Genet (2007) 1.55
Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am J Surg Pathol (2009) 1.55
beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res (2006) 1.55
Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells. Eur Urol (2009) 1.54
Epac increases melanoma cell migration by a heparan sulfate-related mechanism. Am J Physiol Cell Physiol (2009) 1.54
Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning). J Am Coll Cardiol (2013) 1.54
Structural based insights into the role of troponin in cardiac muscle pathophysiology. J Muscle Res Cell Motil (2005) 1.53
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res (2008) 1.53
Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer (2010) 1.51